Novartis: positive results in melanoma and ophthalmology.
(CercleFinance.com) - GSK's Tafinlar, in combination with Novartis' Mekinist, reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma, Novartis said on Monday.
Results from the study, which met its primary endpoint, found a statistically significant reduction in the risk of death or recurrence in patients treated versus placebo.
The Phase III study involved 870 patients with stage III BRAF V600E/K mutation-positive melanoma after complete surgical resection.
Novartis also unveiled new data confirming Lucentis' efficacy and durability in patients with neovascular age-related macular degeneration (nAMD).
The one-year interim results from a Phase IV head-to-head study compared Lucentis versus Sanofi's aflibercept using a treat-and-extend treatment regimen in patients with nAMD.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Results from the study, which met its primary endpoint, found a statistically significant reduction in the risk of death or recurrence in patients treated versus placebo.
The Phase III study involved 870 patients with stage III BRAF V600E/K mutation-positive melanoma after complete surgical resection.
Novartis also unveiled new data confirming Lucentis' efficacy and durability in patients with neovascular age-related macular degeneration (nAMD).
The one-year interim results from a Phase IV head-to-head study compared Lucentis versus Sanofi's aflibercept using a treat-and-extend treatment regimen in patients with nAMD.
Copyright (c) 2017 CercleFinance.com. All rights reserved.